ATE479760T1 - Universelles signalpeptid gas1 - Google Patents

Universelles signalpeptid gas1

Info

Publication number
ATE479760T1
ATE479760T1 AT05729650T AT05729650T ATE479760T1 AT E479760 T1 ATE479760 T1 AT E479760T1 AT 05729650 T AT05729650 T AT 05729650T AT 05729650 T AT05729650 T AT 05729650T AT E479760 T1 ATE479760 T1 AT E479760T1
Authority
AT
Austria
Prior art keywords
heavy chain
chain variable
variable domain
immunoglobulin heavy
domain polypeptide
Prior art date
Application number
AT05729650T
Other languages
English (en)
Inventor
Wildt Rudolph De
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Application granted granted Critical
Publication of ATE479760T1 publication Critical patent/ATE479760T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/055—Fusion polypeptide containing a localisation/targetting motif containing a signal for localisation to secretory granules (for exocytosis)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Gas Separation By Absorption (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05729650T 2004-03-24 2005-03-24 Universelles signalpeptid gas1 ATE479760T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576404P 2004-03-24 2004-03-24
PCT/GB2005/001180 WO2005093074A1 (en) 2004-03-24 2005-03-24 Gas1 universal leader

Publications (1)

Publication Number Publication Date
ATE479760T1 true ATE479760T1 (de) 2010-09-15

Family

ID=34963448

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05729650T ATE479760T1 (de) 2004-03-24 2005-03-24 Universelles signalpeptid gas1

Country Status (11)

Country Link
US (1) US7846721B2 (de)
EP (2) EP2172553A1 (de)
AT (1) ATE479760T1 (de)
CY (1) CY1111063T1 (de)
DE (1) DE602005023291D1 (de)
DK (1) DK1737962T3 (de)
ES (1) ES2351509T3 (de)
PL (1) PL1737962T3 (de)
PT (1) PT1737962E (de)
SI (1) SI1737962T1 (de)
WO (1) WO2005093074A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ555464A (en) 2004-12-02 2010-03-26 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
AU2008259590A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
ES2688621T3 (es) 2008-12-05 2018-11-05 Glaxo Group Limited Métodos para seleccionar polipéptidos resistentes a proteasa
EP2398827A2 (de) 2009-02-19 2011-12-28 Glaxo Group Limited Verbesserte anti-tnfr1-polypeptide, variable antikörperdomänen und antagonisten
BRPI1013341B1 (pt) 2009-02-19 2021-09-08 Glaxo Group Limited Variantes de domínio variável único de imunoglobulina anti-albumina de soro, ligante multiespecífico e composição que compreendem as ditas variantes, bem como ácidos nucleicos e vetor
PE20120170A1 (es) 2009-02-19 2012-03-21 Glaxo Group Ltd Variantes de union a anti-albumina de suero mejoradas
JP2012532619A (ja) 2009-07-16 2012-12-20 グラクソ グループ リミテッド Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
US8679496B2 (en) 2009-07-16 2014-03-25 Glaxo Group Limited Anti-serum albumin single variable domains
EA026097B1 (ru) 2009-07-29 2017-03-31 Глаксо Груп Лимитед Однодоменные антитела против рецептора tgf-бета ii типа
EP2523686A2 (de) 2010-01-14 2012-11-21 Glaxo Group Limited Auf die leber gerichtete domänen-antikörper
JP2013528362A (ja) 2010-04-21 2013-07-11 グラクソ グループ リミテッド 結合ドメイン
US9040668B2 (en) 2010-05-20 2015-05-26 Glaxo Group Limited Anti-serum albumin binding variants
WO2012021749A1 (en) * 2010-08-11 2012-02-16 Celula, Inc. Genotyping dna
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
SG188204A1 (en) 2010-08-20 2013-04-30 Glaxo Group Ltd Improved anti-serum albumin binding variants
KR101886898B1 (ko) 2011-01-06 2018-08-08 글락소 그룹 리미티드 Ｔｇｆ-베타 수용체 ｉｉ에 결합하는 리간드
EP2670778A1 (de) 2011-02-02 2013-12-11 Glaxo Group Limited Neuartige antigenbindende proteine
EA030851B1 (ru) 2011-04-21 2018-10-31 Бристол-Майерс Сквибб Компани Полипептиды антитела, которые антагонизируют cd40
CA2877009C (en) * 2012-07-05 2023-10-03 Devin TESAR Expression and secretion system
US10435475B2 (en) 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9400600A (pt) * 1994-02-17 1995-10-24 Finep Financiadora De Estudos Processos para produção de uma protéina recombinante e/ou de glicosilfosfatidilinositol (GPI) em células de microorganismos eucariontes e para a obtenção de leveduras de S. cerevisae; célula de levedura sequência de nucleotídios; meio de cultura; medicamento ou vacina; e produto dos ditos processos
US6555310B1 (en) * 1997-04-04 2003-04-29 Biosite Diagnostics, Inc. Polyclonal libraries
US7094579B2 (en) * 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression

Also Published As

Publication number Publication date
US20070026462A1 (en) 2007-02-01
EP2172553A1 (de) 2010-04-07
DE602005023291D1 (de) 2010-10-14
SI1737962T1 (sl) 2011-01-31
CY1111063T1 (el) 2015-06-11
WO2005093074A1 (en) 2005-10-06
PT1737962E (pt) 2010-12-03
EP1737962A1 (de) 2007-01-03
ES2351509T3 (es) 2011-02-07
US7846721B2 (en) 2010-12-07
EP1737962B1 (de) 2010-09-01
PL1737962T3 (pl) 2011-02-28
DK1737962T3 (da) 2010-12-13

Similar Documents

Publication Publication Date Title
CY1111063T1 (el) Καθολικος οδηγος gas1
DK1831362T3 (da) Syreaktive svampeproteaser
PT1523496E (pt) Produção de misturas de anticorpos de forma recombinante
NZ734307A (en) Antibodies specific for claudin 6 (cldn6)
EA200701443A1 (ru) Синтетические домены иммуноглобулина, обладающие свойствами связывания и сконструированные в участках молекулы, отличных от гипервариабельных участков
JP2014061000A5 (de)
WO2006116657A3 (en) Single-chain antibody with cleavable linker
DE60333793D1 (de) Feste oberfläche für biomolekülabgabe und assay mit hoher durchlaufleistung
WO2008005847A3 (en) Method of producing factor viii proteins by recombinant methods
ATE512980T1 (de) Polypeptide mit beta-glucosidase-aktivität sowie diese codierende polynukleotide
ATE446972T1 (de) Il-1 bindende antikörper und fragmente davon
DK1294876T3 (da) EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse
DK1625164T3 (da) Fremgangsmåde til at påvise proBNP med et monoklonalt antistof, som binder til aminosyrerne 42-46
WO2009130459A3 (en) Epitopes of il-17a and il-17f and antibodies specific thereto
WO2009088924A3 (en) Methods and materials for targeted affinity enhancement
DK1609863T3 (da) Udskilte polypeptider og transmembranpolypeptider samt nucleinsyrer kodende for disse
DE502006009060D1 (de) Verfahren zur fermentativen Herstellung von Antikörpern
DK2261327T3 (da) Nye enantioselektive mikrobielle nitrilhydrataser med bred substratspecificitet
ATE490320T1 (de) Verwendung von acetalen zur isolation von nukleinsäuren
ATE539163T1 (de) Auf der verwendung von mva beruhende impfstoffe
WO2008008182A3 (en) Method of production of para-hydroxycinnamic acid
ATE445009T1 (de) Signalpeptid zur herstellung eines polypeptids
WO2007019064A3 (en) ANTI-TNFα ANTIBODIES AND METHODS OF USE
ATE531799T1 (de) Nukleinsäuremolekül mit fähigkeit zur bindung an aus kaninchen stammenden igg-antikörper
PT1366161E (pt) Anticorpo anatagonista anti-pro842

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1737962

Country of ref document: EP